Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
Wave Life Sciences Ltd (NASDAQ: WVE) closed the day trading at $15.15 up 1.00% from the previous closing price of $15.0. In other words, the price has increased by $1.00 from its previous closing price. On the day, 14.97 million shares were traded. WVE stock price reached its highest trading level at $19.5 during the session, while it also had its lowest trading level at $15.12.
Ratios:
For a better understanding of WVE, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.51 and its Current Ratio is at 2.51. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.09.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on December 12, 2025, Reiterated its Outperform rating but revised its target price to $33 from $20 previously.
On December 09, 2025, RBC Capital Mkts Upgraded its rating to Outperform which previously was Sector Perform but kept the price unchanged to $27.
On October 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $18.Wells Fargo initiated its Overweight rating on October 20, 2025, with a $18 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 02 ’26 when Francis Chris sold 9,375 shares for $16.03 per share. The transaction valued at 150,260 led to the insider holds 25,000 shares of the business.
GSK plc bought 1,470,000 shares of WVE for $27,930,000 on Dec 11 ’25. The 10% Owner now owns 18,245,691 shares after completing the transaction at $19.00 per share. On Dec 08 ’25, another insider, Rawcliffe Adrian, who serves as the Director of the company, sold 42,000 shares for $15.00 each. As a result, the insider received 630,000 and left with 12,700 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, WVE now has a Market Capitalization of 2814262528 and an Enterprise Value of 2363061760. For the stock, the TTM Price-to-Sale (P/S) ratio is 25.38 while its Price-to-Book (P/B) ratio in mrq is 19.50. Its current Enterprise Value per Revenue stands at 21.634 whereas that against EBITDA is -17.842.
Stock Price History:
The Beta on a monthly basis for WVE is -1.77, which has changed by 0.20000005 over the last 52 weeks, in comparison to a change of 0.16623151 over the same period for the S&P500. Over the past 52 weeks, WVE has reached a high of $21.73, while it has fallen to a 52-week low of $5.28. The 50-Day Moving Average of the stock is 33.29%, while the 200-Day Moving Average is calculated to be 79.46%.
Shares Statistics:
Over the past 3-months, WVE traded about 6.40M shares per day on average, while over the past 10 days, WVE traded about 2806640 shares per day. A total of 160.29M shares are outstanding, with a floating share count of 147.79M. Insiders hold about 19.24% of the company’s shares, while institutions hold 75.40% stake in the company. Shares short for WVE as of 1765756800 were 14691352 with a Short Ratio of 2.29, compared to 1763078400 on 15407887. Therefore, it implies a Short% of Shares Outstanding of 14691352 and a Short% of Float of 10.190000000000001.
Earnings Estimates
Wave Life Sciences Ltd (WVE) is currently under the scrutiny of 12.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.29 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.02 and -$1.27 for the fiscal current year, implying an average EPS of -$1.18. EPS for the following year is -$1.21, with 12.0 analysts recommending between -$0.65 and -$1.62.
Revenue Estimates
15 analysts predict $17.12M in revenue. The current quarter. It ranges from a high estimate of $47M to a low estimate of $7.61M. As of. The current estimate, Wave Life Sciences Ltd’s year-ago sales were $83.75M
A total of 15 analysts have provided revenue estimates for WVE’s current fiscal year. The highest revenue estimate was $72.5M, while the lowest revenue estimate was $33.09M, resulting in an average revenue estimate of $42.9M. In the same quarter a year ago, actual revenue was $108.3M
